CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented real-world data on anxiety associated with the use of injectable on-demand treatments for hereditary angioedema (HAE) attacks and patient perspectives on why people living with HAE don’t often carry their on-demand treatment outside the home at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Anaheim, CA..

CAMBRIDGE，Mass。＆SALISBURY，England-（BUSINESS WIRE）-KalVista Pharmaceuticals，Inc。（纳斯达克股票代码：KALV），一家临床阶段制药公司，专注于口服小分子蛋白酶抑制剂的发现，开发和商业化，今天宣布，它提出了与使用可注射按需治疗遗传性血管性水肿（HAE）攻击相关的焦虑的实际数据，以及患者对为什么患有HAE的人不经常在家外进行按需治疗的观点。在加利福尼亚州阿纳海姆的美国过敏，哮喘和免疫学学院（ACAAI）2023年年度科学会议上。。

“We continue to learn from people living with HAE that currently available parenteral on-demand treatments are simply not meeting their needs,” said Andrew Crockett, Chief Executive Officer of KalVista. “Whether this is related to always carrying their syringes or vials, challenges in preparing and administering injectable or infused treatments outside the home, or anxiety related to potential injection-site reactions and pain, patients struggle to follow treatment guidelines.

卡维斯塔首席执行官安德鲁·克罗克特（Andrew Crockett）说：“我们继续向患有HAE的人学习，目前可用的肠胃外按需治疗根本无法满足他们的需求。“无论这是否与始终携带注射器或小瓶有关，在家外准备和管理注射或输注治疗的挑战，或与潜在注射部位反应和疼痛相关的焦虑，患者都难以遵循治疗指南。

This can lead to non-compliance and preference for long-term prophylaxis, even in cases where on-demand treatments would otherwise suffice. We also note that despite the use of long-term prophylaxis, HAE patients require HAE-related home health visits and seek ER treatment more often than would be expected.

即使在按需治疗就足够的情况下，这也可能导致不遵守和偏好长期预防。我们还注意到，尽管使用了长期预防措施，但HAE患者仍需要与HAE相关的家庭健康访问，并且寻求ER治疗的频率比预期的要高。

It is our hope that if sebetralstat is approved for the on-demand treatment of HAE, it may be able to address this significant unmet need and help transform the management of the disease.”.

我们希望，如果sebetralstat被批准用于HAE的按需治疗，它可能能够解决这一重大未满足的需求并帮助改变疾病的管理。”。

In addition to the data on persisting non-medication health resource utilization among patients receiving long-term prophylaxis, the Company presented data on the global prevalence of HAE-nC1-INH the approach to the presumptive diagnosis, and the highly varied treatment approaches that represent another significant area of unmet need in that population..

除了接受长期预防的患者持续使用非药物卫生资源的数据外，该公司还提供了有关HAE-nC1-INH全球流行率的数据-推定诊断方法以及各种各样的治疗方法该人群中另一个未满足需求的重要领域。。

The following presentations occurred at ACAAI 2023:

以下演示文稿发生在ACAAI 2023：

Anxiety Associated with On-Demand Treatment of HAE Attacks May Result in Suboptimal Attack Management: Michael Manning, Allergy, Asthma & Immunology Associates, Ltd., Internal Medicine, UA College of Medicine-Phoenix, Scottsdale, Arizona, United States (Poster Presentation)

与按需治疗HAE发作相关的焦虑可能导致次优的发作管理：Michael Manning，Allergy，Asthma＆Immunology Associates，Ltd.，UA College of Medicine Phoenix，Scottsdale，Arizona，United States（海报展示）

Understanding Why Hereditary Angioedema Patients Often Do Not Carry Their On-Demand Treatment with Them: Bob Geng, Allergy and Immunology, University of California, San Diego, California, United States (Poster Presentation)

了解为什么遗传性血管性水肿患者通常不按需进行治疗：Bob Geng，美国加利福尼亚大学圣地亚哥分校过敏与免疫学（海报展示）

Treatment Patterns Among Individuals with Hereditary Angioedema in the United States: Raffi Tachdjian, University of California, Los Angeles, Los Angeles, CA, United States (Poster Presentation)

美国遗传性血管性水肿患者的治疗模式：Raffi Tachdjian，加州大学洛杉矶分校，洛杉矶，加利福尼亚州，美国（海报展示）

Refining Prevalence Estimates of Hereditary Angioedema (HAE) with Normal C1-INH (HAE-nC1-INH): Markus Magerl, Angioedema Center of Reference and Excellence (ACARE), Institute of Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany (Poster Presentation).

用正常C1-INH（HAE-nC1-INH）改进遗传性血管性水肿（HAE）的患病率估计：Markus Magerl，参考和卓越血管性水肿中心（ACARE），柏林Charité-Universitätsmedizin过敏研究所，FreieUniversität的公司成员柏林和德国柏林洪堡大学（海报展示）。

Diagnosing Hereditary Angioedema (HAE) with Normal C1-INH (HAE-nC1-INH) –A Real World ACARE Survey: Marc A. Riedl, Division of Rheumatology, Allergy and Immunology, University of California –San Diego, San Diego, California, United States (Poster Presentation)

用正常的C1-INH（HAE-nC1-INH）诊断遗传性血管性水肿（HAE）-现实世界的ACARE调查：Marc A.Riedl，加州大学圣地亚哥分校风湿病学，变态反应和免疫学系，美国加利福尼亚州（海报展示）

Treatment of Hereditary Angioedema (HAE) with Normal C1-INH (HAE-nC1-INH) –A Real-World ACARE Survey: Marcus Maurer, Angioedema Center of Reference and Excellence (ACARE), Institute of Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany (Poster Presentation).

用正常C1-INH（HAE-nC1-INH）治疗遗传性血管性水肿（HAE）-现实世界的ACARE调查：Marcus Maurer，血管性水肿参考和卓越中心（ACARE），过敏研究所，Charité-UniversitätsmedizinBerlin，公司成员柏林自由大学和德国柏林洪堡大学（海报展示）。

Links to all posters and presentations can be found on the KalVista website under “Publications”.

所有海报和演示文稿的链接都可以在KalVista网站的“出版物”下找到。

About KalVista Pharmaceuticals, Inc.

关于KalVista制药公司。

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the phase 3 KONFIDENT clinical trial.

KalVista Pharmaceuticals，Inc。是一家制药公司，专注于口服，小分子蛋白酶抑制剂的发现，开发和商业化，用于具有显着未满足需求的疾病。KalVista正在开发sebetralstat作为HAE攻击的口服按需治疗，并已实现3期KONFIDENT临床试验的目标招募。

In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases..

此外，KalVista的口服因子XIIa抑制剂计划代表了新一代疗法，可以进一步改善对HAE和其他疾病患者的治疗。。

For more information about KalVista, please visit www.kalvista.com.

有关KalVista的更多信息，请访问www.KalVista.com。

For more information on the sebetralstat HAE on-demand Phase 3 KONFIDENT study, please visit www.konfidentstudy.com.

有关sebetralstat HAE按需3期KONFIDENT研究的更多信息，请访问www.konfidentstudy.com。

Forward-Looking Statements

前瞻性声明

This press release contains 'forward-looking' statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'anticipate,' 'intend,' 'plan,' 'goal,' 'seek,' 'believe,' 'project,' 'estimate,' 'expect,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'will' and similar references to future periods.

本新闻稿包含1995年“美国私人证券诉讼改革法案”安全港条款范围内的“前瞻性”声明。前瞻性陈述可以用诸如“预期”，“打算”，“计划”，“目标”，“寻求”，“相信”，“项目”，“估计”，“期望”，“策略”，“未来”，“可能”，“可能”，“应该”，“将会”以及对未来时期的类似引用。

These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 3 KONFIDENT trial, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program.

这些陈述存在许多风险和不确定性，可能导致实际结果与我们的预期大不相同。前瞻性陈述的例子包括，其中包括与FDA沟通的时间或结果，我们对产品候选人的安全性和有效性以及临床试验时间及其结果的期望，我们开始临床研究或完成正在进行的临床研究的能力包括我们的3期KONFIDENT试验，并获得sebetralstat和其他正在开发的候选人的监管批准，sebetralstat商业化的任何努力的成功，sebetralstat和其他正在开发的候选人治疗HAE或其他疾病的能力，以及我们口腔因子XIIa的未来进展和潜在成功计划。

Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2023, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission.

有关可能影响我们业务和财务结果的潜在风险因素的更多信息，请参阅我们与证券交易委员会的文件，包括我们在2023年4月30日结束的年度10-K年度报告，我们的季度报告表格10-Q，以及我们可能与证券交易所不时发布的其他报告。

We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, futu.

我们不承担任何义务公开更新可能由于新信息futu而不时发布的任何前瞻性声明，无论是书面还是口头。